# SR One

> SR One is a VC fund in Cambridge backing Biotechnology and Health Care. See 198 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 198
- Last investment: Jul 2026
- Lead investor: 33%
- Last fund: Mar 2023
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/sr-one
- Website: http://www.srone.com

SR One is a VC fund in Cambridge focused on Biotechnology and Health Care. SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately 800 million in more than 180 companies.

## Contacts

5 contacts available for SR One. Shizune tracks 9 team members at SR One. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sr-one?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $3.7M–$100M |
| Series B | $15M–$114M |
| Series C | $22M–$175M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 79 | 40% |
| Health Care | 58 | 29% |
| Therapeutics | 39 | 20% |
| Medical | 35 | 18% |
| Pharmaceutical | 29 | 15% |

35 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 49 | 25% |
| Series B | 44 | 22% |
| Series C | 33 | 17% |
| Series D | 13 | 7% |
| Funding Round | 10 | 5% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 74 | 37% |
| United Kingdom | 11 | 6% |
| Canada | 3 | 2% |
| Switzerland | 3 | 2% |
| Israel | 2 | 1% |

11 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jill Carroll | Partner | 10 | https://shizune.co/investors/profile/jill-carroll |
| Simeon George | Chief Executive Officer | 24 | https://shizune.co/investors/profile/simeon-j-george |
| Christopher Y. Chai | Venture Partner | 0 | https://shizune.co/investors/profile/christopher-y-chai |
| Iqbal Mufti | Partner | 3 | https://shizune.co/investors/profile/iqbal-mufti-e58a |
| Jens Eckstein | President | 18 | https://shizune.co/investors/profile/jens-eckstein |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Crystalys Therapeutics | Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. | $130M | Series B | Jul 22, 2026 |  |
| Fore Biotherapeutics | We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $67.4M | Series D | Jul 07, 2026 |  |
| Fore Biotherapeutics | We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $67.4M | Series D | Jul 07, 2026 |  |
| Fore Biotherapeutics | We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $67.4M | Series D | Jul 07, 2026 |  |
| Windward Bio | Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M | Series B | May 04, 2026 |  |
| Immutrin | Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils. | $87.1M | Series A | Mar 24, 2026 |  |
| CORXEL Pharmaceuticals | Jixing Pharmaceuticals develops innovative science and medicines to underserved Chinese patients with serious and life-threatening diseases. | $287M | Series D | Jan 22, 2026 |  |
| AirNexis Therapeutics | AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions. | $200M | Series A | Jan 09, 2026 |  |
| Poplar Therapeutics | Poplar Therapeutics anti-IgE therapy treats atopic diseases such as food allergy, allergic asthma, and atopic dermatitis. | $50M | Series A | Jan 07, 2026 |  |
| Addition Therapeutics | Addition Therapeutics focuses on developing RNA-only therapeutics using its proprietary PRINT technology. This approach enables the precise insertion of genetic elements at specific safe harbor sites, aiming to transform the field of genetic medicine. They operate within the biotechnology industry and are backed by venture capital. Their innovativemethods target gene editing and regulation, potentially offering new solutions in the field of genetic therapies. | $100M | Series A | Dec 17, 2025 |  |

10 of 198 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 34 deals together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 20 deals together
- [Pfizer Venture Investments](https://shizune.co/investors/profile/pfizer-venture-investments) — VC Fund, 20 deals together
- [Roche Venture Fund](https://shizune.co/investors/profile/roche-venture-fund) — VC Fund, 19 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 18 deals together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 17 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Investinor](https://shizune.co/investors/profile/investinor) — VC Fund
- [Skyfall Ventures](https://shizune.co/investors/profile/skyfall-ventures) — VC Fund

## Featured in investor lists
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)
- [Health Care Investors](https://shizune.co/investors/health-care-investors)
- [Health Care VC Funds](https://shizune.co/investors/health-care-vc-funds)

## FAQ

### What does SR One invest in?

SR One invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 198 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is SR One's check size?

SR One typically joins rounds of $3.7M–$100M at Series A, $15M–$114M at Series B and $22M–$175M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds SR One participates in.

### How do I contact SR One?

Public channels for SR One include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at SR One?

The team at SR One includes Jill Carroll (Partner), Simeon George (Chief Executive Officer) and Christopher Y. Chai (Venture Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co